PL3613768T3 - Przeciwciało monoklonalne antagonizujące i hamujące wiązanie ludzkiego antygenu pd-1 z jego ligandem, sposób jego wytwarzania i zatosowanie - Google Patents

Przeciwciało monoklonalne antagonizujące i hamujące wiązanie ludzkiego antygenu pd-1 z jego ligandem, sposób jego wytwarzania i zatosowanie

Info

Publication number
PL3613768T3
PL3613768T3 PL17906230.2T PL17906230T PL3613768T3 PL 3613768 T3 PL3613768 T3 PL 3613768T3 PL 17906230 T PL17906230 T PL 17906230T PL 3613768 T3 PL3613768 T3 PL 3613768T3
Authority
PL
Poland
Prior art keywords
antigen
ligand
human
preparation
application
Prior art date
Application number
PL17906230.2T
Other languages
English (en)
Inventor
Hongqun Hu
Zui CHEN
Xiaoqi SONG
Shiping Luo
Mingwen CAI
Jinling FAN
Yiqing Xu
Qunmin Zhou
Original Assignee
Acroimmune Biopharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acroimmune Biopharmaceutical Co., Ltd. filed Critical Acroimmune Biopharmaceutical Co., Ltd.
Publication of PL3613768T3 publication Critical patent/PL3613768T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL17906230.2T 2017-04-20 2017-06-21 Przeciwciało monoklonalne antagonizujące i hamujące wiązanie ludzkiego antygenu pd-1 z jego ligandem, sposób jego wytwarzania i zatosowanie PL3613768T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710262053.4A CN106939049B (zh) 2017-04-20 2017-04-20 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
PCT/CN2017/089282 WO2018192089A1 (zh) 2017-04-20 2017-06-21 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用

Publications (1)

Publication Number Publication Date
PL3613768T3 true PL3613768T3 (pl) 2024-05-06

Family

ID=59464668

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17906230.2T PL3613768T3 (pl) 2017-04-20 2017-06-21 Przeciwciało monoklonalne antagonizujące i hamujące wiązanie ludzkiego antygenu pd-1 z jego ligandem, sposób jego wytwarzania i zatosowanie

Country Status (10)

Country Link
US (1) US11345754B2 (pl)
EP (1) EP3613768B1 (pl)
JP (1) JP6928971B2 (pl)
CN (1) CN106939049B (pl)
ES (1) ES2969235T3 (pl)
HR (1) HRP20240102T1 (pl)
HU (1) HUE065954T2 (pl)
PL (1) PL3613768T3 (pl)
RS (1) RS64987B1 (pl)
WO (1) WO2018192089A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102451510B1 (ko) 2016-09-08 2022-10-07 2세븐티 바이오, 인코포레이티드 Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
CN108299561B (zh) * 2018-01-02 2020-11-13 暨南大学 一种pd-1纳米抗体及其克隆表达方法与应用
CN108997497B (zh) 2018-03-30 2022-02-25 华兰基因工程有限公司 特异结合人质膜膜泡关联蛋白pv-1的单克隆抗体及其制备方法与应用
CN110878122B (zh) * 2018-09-06 2023-07-28 上海张江生物技术有限公司 重组抗pd-l1单克隆抗体
CN109053892B (zh) 2018-09-19 2021-03-26 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
JP2022513750A (ja) 2018-12-10 2022-02-09 ２セブンティ バイオ インコーポレイテッド ホーミングエンドヌクレアーゼバリアント
IL283724B1 (en) * 2018-12-10 2026-02-01 Genetix Biotherapeutics Inc pdcd-1 homing endonuclease variants
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
US20220332825A1 (en) 2019-08-08 2022-10-20 Ono Pharmaceutical Co., Ltd. Bispecific protein
CN115038718B (zh) * 2019-11-08 2024-07-02 山东先声生物制药有限公司 抗人程序性死亡配体-1（pd-l1）的抗体及其用途
CN113563470B (zh) * 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
KR20260005250A (ko) 2023-04-28 2026-01-09 온코씨4, 아이앤씨. 항-ctla-4 항체와 항-pd-1 항체의 조합 및 이의 치료적 용도
WO2025193962A1 (en) * 2024-03-15 2025-09-18 OncoC4, Inc. Anti-vegf and pd-1 bispecific antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
JP6072771B2 (ja) * 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
SMT202100065T1 (it) * 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
CN103242448B (zh) 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN112552401B (zh) * 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN104560884A (zh) * 2013-10-25 2015-04-29 苏州思坦维生物技术有限责任公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及分泌它的杂交瘤细胞系与用途
CN104558177B (zh) * 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
PE20170255A1 (es) * 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
WO2016008067A1 (zh) 2014-07-14 2016-01-21 惠州市吉瑞科技有限公司 一种吸烟控制方法、吸烟控制电路以及电子烟
KR102357893B1 (ko) * 2014-08-05 2022-02-04 맵퀘스트 에스아 Pd-1 에 결합하는 면역학적 시약
DK3237446T3 (en) * 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
CN105061597B (zh) 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
EP4458417A3 (en) * 2015-08-11 2025-02-19 Wuxi Biologics Ireland Limited Novel anti-pd-1 antibodies
ES2924402T3 (es) * 2015-10-02 2022-10-06 Symphogen As Anticuerpos anti-PD-1 y composiciones

Also Published As

Publication number Publication date
EP3613768A1 (en) 2020-02-26
JP6928971B2 (ja) 2021-09-01
US11345754B2 (en) 2022-05-31
CN106939049B (zh) 2019-10-01
EP3613768A4 (en) 2020-06-17
WO2018192089A1 (zh) 2018-10-25
EP3613768B1 (en) 2023-11-22
RS64987B1 (sr) 2024-01-31
CN106939049A (zh) 2017-07-11
ES2969235T3 (es) 2024-05-17
HRP20240102T1 (hr) 2024-03-29
JP2020517264A (ja) 2020-06-18
HUE065954T2 (hu) 2024-07-28
EP3613768C0 (en) 2023-11-22
US20200277376A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
PL3613768T3 (pl) Przeciwciało monoklonalne antagonizujące i hamujące wiązanie ludzkiego antygenu pd-1 z jego ligandem, sposób jego wytwarzania i zatosowanie
EP3822290A4 (en) SEMA4D ANTIBODY, METHOD FOR PREPARATION AND USE
EP3878869A4 (en) NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF
ZA202004494B (en) Anti-tmprss2 antibodies and antigen-binding fragments
ZA201908072B (en) Igf-1r monoclonal antibodies and uses thereof
IL269593A (en) Anti-ILT4 antibodies and antigen-binding fragments
IL260218A (en) Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
ZA201700528B (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
ZA201900792B (en) Anti-pd-1 antibodies, method for producing same and method for using same
EP3176182A4 (en) Anti-pd-1 monoclonal antibody and obtaining method therefor
ZA201906004B (en) Anti-par2 antibodies and uses thereof
IL274121A (en) Bispecific antibodies that bind ALK-1 and BMPR-2
ZA202003858B (en) Monoclonal antibodies and methods for using same
WO2016014688A3 (en) Anti-pd-1 antibodies
SG11202104373YA (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
SG10201808519VA (en) Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
EP3321284A4 (en) Monoclonal antibody of human procalcitonin, preparation method therefor, and application thereof
WO2016205427A3 (en) Binding proteins against vegf, pdgf, and/or their receptors
SG11202011201QA (en) Fully human antibodies against ox40, method for preparing same, and use thereof
SG11202012148RA (en) Monoclonal antibodies against human tim-3
IL321888B1 (en) Antibodies that bind 1-PD and their uses
EP3730518A4 (en) MONOCLONAL ANTIBODY BINDING TO HUMAN IL-5, METHOD FOR PREPARATION AND USE
EP4082572A4 (en) ANTI-CTLA-4 MONOCLONAL ANTIBODY, PREPARATION METHOD AND ITS APPLICATION
EP3587452A4 (en) ANTI-TIM-3 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF IT, AND MEDICAL USES OF IT
EP3242895A4 (en) A novel anti-egfr monoclonal antibody, method of making, and use thereof